Vaginal Laser Therapy in Breast Cancer Survivors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
Kiungo kimehifadhiwa kwenye clipboard
HaliKuajiri
Wadhamini
National and Kapodistrian University of Athens
JARIBIO LA KLINIKI: NCT03738605
BioSeek: nct03738605
Maneno muhimu
Kikemikali
This study evaluates the efficacy of vaginal CO2 laser therapy in breast cancer survivors with symptoms of Genitourinary Syndrome of Menopause. Half of participants will receive active laser therapy, while the other half placebo therapy.
Tarehe
| Imethibitishwa Mwisho: | 06/30/2019 |
| Iliyowasilishwa Kwanza: | 11/05/2018 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 11/07/2018 |
| Iliyotumwa Kwanza: | 11/12/2018 |
| Sasisho la Mwisho Liliwasilishwa: | 07/27/2019 |
| Sasisho la Mwisho Lilichapishwa: | 07/29/2019 |
| Tarehe halisi ya kuanza kwa masomo: | 11/30/2018 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 05/31/2020 |
| Tarehe ya Kukamilisha Utafiti: | 07/31/2020 |
Hali au ugonjwa
Genitourinary Syndrome of Menopause
Vaginal Atrophy
Breast Cancer
Dyspareunia
Uingiliaji / matibabu
Device: Microablative Fractional CO2 Laser Therapy
Awamu
-
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Experimental: Laser Group Microablative Fractional CO2 Laser Therapy (The parameters that will be used are the following: 1) Power: 30 ή 40 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter from 1-3 depending on the treatment status, 5) D-pulse mode.) | |
| Placebo Comparator: Placebo Placebo therapy (The parameters that will be used are the following: 1) Power: 0.5 watts, 2) Dwell time:1000μs, 3) Spacing 1000 μm, 4) Depth: SmartStak parameter 1, 5) Smart-pulse mode. |
Vigezo vya Kustahiki
| Jinsia Inastahiki Kujifunza | Female |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: - breast cancer history - dyspareunia - dryness Exclusion Criteria: - Active genital infection (i.e herpes, vaginitis) - Prolapse stage >=2 - Underlying pathologies that could interfere with the protocol compliance |
Matokeo
Hatua za Matokeo ya Msingi
1. 10-centimeter Visual Analogue Scale assessing intensity of dyspareunia and dryness [Change from baseline at 1 month post-treatment]
It is a straight line with 2 endpoints "0" and "10". Zero defines "no dyspareunia at all" and "no dryness at all" , while 10 "dyspareunia as bad as it could be" and "dryness as bad as it could be". Participants will draw a line at or between the 2 end points. The distance between zero and drawn line will define the intensity of dyspareunia and dryness
Hatua za Matokeo ya Sekondari
1. 3 days voiding diary [Change from baseline at 1 month post-treatment]
Assesses frequency of urination, amount of urine, presence of urgency and/or urinary incontinence and amount of fluid intake
2. Day-to Day Impact of vaginal aging questionnaire (DIVA) [Change from baseline at 1 month post-treatment]
It includes 4 domains: activities of daily living (5 items), sexual functioning (5 items), emotional well-being (4 items), self-concept and body image (5-items). Each item of each domain could receive values from 0 to 4. Mean scores are calculated on each of the domain scales. Higher scores indicate greater symptom impact
3. Patients Global Impression of Improvement [At 1-month post-treatment]
It is a single item questionnaire assessing the impression of participants following the intervention
4. 10-centimeter Visual Analogue Scale assessing intensity of itching, burning and dysuria [Change from baseline at 1 month post-treatment]
It is a straight line with 2 endpoints "0" and "10". Zero defines "no symptom (itching, burning and dysuria) at all" , while 10 "symptom (itching, burning and dysuria) as bad as it could be". Participants will draw a line at or between the 2 end points. The distance between zero and drawn line will define the intensity of itching, burning and dysuria
5. King's Health Questionnaire (KHQ) [Change from baseline at 1 month post-treatment]
It has 3 sections: 1) general health and overall health related to urinary symptoms with 2 questions, 2) incontinence impact, role limitations, physical limitations, social limitations, personal limitations, emotions, sleep and energy, and severity coping measures with 19 questions and 3) bother or impact of urinary symptoms with 11 questions. Scores of each domain of the 2 sections range from 0 to 100. Scores of the third section range from 0 to 3. Higher scores indicate higher impact of urinary incontinence.
6. Female Sexual Function Index [Change from baseline at 1 month post-treatment]
It is a questionnaire defining women's sexual function. It includes 6 domains: desire, arousal, orgasm, lubrication, satisfaction and pain. The answer of each Question in each domain are multiplied by a certain factor. Total score is calculated by summing the scores of the all domains with a minimum value of 2 and a maximum of 36. The highest the total score the better is the sexual functioning. Total score above 26.55 defines normal sexual function
7. Vaginal Maturation Value [6 months]
It is calculated by defining the percentage of superficial, intermediate and parabasal epithelial cells on the vaginal pap smear, following the formula (1x%superficial)+(0.5x%intermediate)+(0x%parabasal). It may receive values from 0 to 100%.It is considered to be an indicator of the estrogenic stimulation, whereas values of 0-49%, 50-64% and 65-100% indicate absent/low, moderate and high estrogenic effect on the vaginal epithelium, respectively.
8. Vaginal Health Index Score [6 months]
It evaluates vaginal elasticity, fluid volume, ph of vaginal fluid, epithelial integrity and moisture. Each one of these may receive scores from 1 to 5. Total score is calculated by summing the 5 scores ranging from 5 to 25. Higher scores indicate better vaginal status.
9. International Consultation on Incontinence Questionnaire Short Form [6 months]
it is a questionnaire with 4 questions assessing the amount of leakage, frequency and type of urinary incontinence. Total score is calculated by summing the 3 out of the 4 questions. Higher scores indicate worst urinary incontinence
10. Modified Sexual Quality of Life Questionnaire-Male [6 months]
It includes 12 questions assessing the quality of life and sexual satisfaction of the male partner. Each answer may receive values from 1 to 5. The higher the scores the better subjective evaluation of sexual quality of life
11. Urogenital Distress Inventory 6 [6 months]
It is a condition specific questionnaire containing 6 questions. The answers of questions assesses the presence of symptoms and the degree of bother on a 4-point scale ("not at all", "a little bit", "moderately" and "greatly" applying to 0, 1, 2 and 3, respectively). Total score is calculated by summing the score of each question. The higher the total score the highest is the symptom bother
12. Epithelial thickness [6 months]
Biopsies will be obtained from the lateral vaginal wall. Epithelial thickness (in μ) will be measured by a vertical line between basal layer cells and superficial layers.
13. Number of blood vessels [6 months]
Biopsies will be obtained from the lateral vaginal wall. Computerized determination of blood vessels number will be performed
14. Size of blood vessels [6 months]
Biopsies will be obtained from the lateral vaginal wall. Computerized determination of the blood vessels size will be performed
15. Collagen [6 months]
Biopsies will be obtained from the lateral vaginal wall. Determination of collagen types using immunohistochemistry and microscopy.
